Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.40 |
| ▸ | TACR2 | P21452 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6544366 | 0.95 | SLC6A3 (0.38) | TACR1TACR2MEN1KMT2ASLC6A4 | |
| SCHEMBL6950573 | 0.94 | TACR1 (0.39) | TACR1TACR2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7956526 | 0.91 | MEN1 (0.38) | TACR1TACR2MEN1KMT2ASLC6A4 | |
| SCHEMBL7766689 | 0.90 | SLC6A3 (0.39) | TACR1TACR2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3466870 | 0.86 | SLC6A4 (0.36) | TACR1TACR2MEN1KMT2ASLC6A4 | |
| SCHEMBL4630820 | 0.85 | MEN1 (0.39) | TACR1TACR2MEN1KMT2ASLC6A4 | |
| SCHEMBL7947168 | 0.85 | SLC6A2 (0.48) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL7765670 | 0.85 | SLC6A3 (0.39) | TACR1TACR2MEN1KMT2ASLC6A4 | |
| SCHEMBL8290900 | 0.84 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL7085751 | 0.84 | SLC6A4 (0.40) | TACR1TACR2SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0512901-B1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-06-23 | — | — | EP | claimed |
| EP-1101757-A1 | Heterocyclic compounds as tachykinin receptor antagonists | SANOFI-SYNTHELABO (FR) | 2001-05-23 | — | — | EP | disclosed |
| US-6124319-A | TREATING INFLAMMATORY AND IMMUNOREGULATORY DISORDERS AND DISEASES, INCLUDING ASTHMA AND ALLERGIC DISEASES, AUTOIMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS | MERCK & CO., INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0512901-B1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-06-23 | — | — | EP | disclosed |
| US-5859029-A | TREATING SUBSTANCE P-DEPENDENT PATHOLOGICAL CONDITIONS | SANOFI (FR) | 1999-01-12 | — | — | US | disclosed |
| US-5770735-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-23 | — | — | US | disclosed |
| US-5656639-A | POSSESS STRONG AFFINITY FOR NK1 RECEPTORS; USEFUL IN TREATMENT OF SUBSTANCE P-DEPENDENT PATHOLOGICAL CONDITIONS | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| US-5625060-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present | Sanofi, Elf (FR) | 1997-04-29 | — | — | US | disclosed |
| EP-0723959-A1 | Heterocyclic compounds as tachykinin receptor antagonists, process for their preparation and pharmaceuticals containing them | SANOFI (FR) | 1996-07-31 | — | — | EP | disclosed |
| US-5340822-A | Substance P, neurokinin antagonists | ELF SANOFI (FR) | 1994-08-23 | — | — | US | disclosed |
| EP-0512901-A1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-11 | — | — | EP | disclosed |